Talk Bio

J&J's experimental use of Erleada in early-stage prostate cancer has shown promising yet mixed results in recent trials, particularly in high-risk localized or locally advanced disease. *** In a large late-stage trial in high-risk localized or locally advanced prostate cancer, adding Erleada to standard hormone-blocking therapy (androgen deprivation therapy) before and after prostate surgery improved outcomes:** patients were more than nine times more likely to have little or no detectable cancer in the prostate at surgery (8.9% vs about 1% in the hormone‑therapy‑alone group).* The combination also reduced the risk of disease progression or death by 20% and prolonged the time until patients needed further treatment by roughly double compared with hormone therapy alone. Despite these clear benefits, questions remain amongst experts about the optimal treatment strategy: * There is debate over whether an intensive, longer course of Erleada plus hormone therapy actuall...